Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713133 | 0.87 | GPR119 (0.38) | GPR119 | |
| SCHEMBL2371910 | 0.84 | GPR119 (0.44) | GPR119KCNH2 | |
| SCHEMBL2370710 | 0.80 | GPR119 (0.45) | GPR119KCNH2 | |
| SCHEMBL1712882 | 0.76 | GPR119 (0.41) | GPR119KCNH2 | |
| SCHEMBL1712481 | 0.72 | GPR119 (0.53) | GPR119KCNH2 | |
| SCHEMBL2568018 | 0.72 | ACACB (0.39) | GPR119KCNH2 | |
| SCHEMBL2568023 | 0.72 | ACACB (0.39) | GPR119KCNH2 | |
| SCHEMBL2371660 | 0.71 | GPR119 (0.56) | GPR119KCNH2 | |
| SCHEMBL1713600 | 0.70 | GPR119 (0.47) | GPR119KCNH2 | |
| SCHEMBL1713594 | 0.70 | GPR119 (0.47) | GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | claimed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | claimed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | claimed |
| US-20130310398-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-21 | — | — | US | disclosed |
| US-8513264-B2 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-20 | — | — | US | disclosed |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-02 | — | — | US | disclosed |
| EP-2547339-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2011113947-A1 | COMBINATION OF A GPR119 AGONIST AND THE DPP-IV INHIBITOR LINAGLIPTIN FOR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | WO | disclosed |
| EP-2344195-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Boehringer Ingelheim International GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010029089-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | WO | disclosed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310398-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | GPR119 1/4885NR1H2 309/4885NR1H3 421/4885 |
| US-20100048631-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GPR119 1/4885NR1H2 110/4885NR1H3 145/4885 |
| US-20110263617-A1 | Combination therapy for the treatment of diabetes and related conditions | GPR119, DPP4, GLP1R | GPR119 1/4885NR1H2 247/4885NR1H3 307/4885 |
| US-20130109703-A1 | Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions | GPR119, DPP4, GLP1R | GPR119 1/4885NR1H2 490/4885NR1H3 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.